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Abstract 
 Growing evidence suggests that -lipoic acid (LA) has neuroprotective effects in 
various pathological conditions including brain ischemia and neurodegeneration. While 
anti-oxidative activity has been thought to play a central role in LA-mediated neuroprotection, 
the precise mechanism and the effect of LA enantiomers (R- and S-LA) are not fully clarified. 
We, therefore, estimated the neuroprotective effects of LA against different cellular stresses 
including oxidative stress, endoplasmic reticulum (ER) stress and proteolytic stress using 
human neuroblastoma SH-SY5Y cells. All types of LAs (racemate, R-LA and S-LA) most 
effectively prevented cell death induced by buthionine sulfoximine (BSO) which depletes 
intracellular glutathione. Although direct effects of LA on glutathione depletion or generation 
of the reactive oxygen species (ROS) were relatively small upon BSO treatment, LA 
enhanced expressions of anti-oxidative genes such as heme oxygenase-1 (HO-1) and phase II 
detoxification enzymes such as NAD(P)H:Quinone Oxidoreductase 1 (NQO1). An inhibitor 
of NQO1, but not that of HO-1, suppressed LA-mediated protection against BSO. Further 
experiments revealed that all types of LAs activated cell survival-associated kinase Akt, and 
an inhibitor of PI3K, LY294002, suppressed both LA-induced upregulation of NQO1 and 
cell protection against BSO. Our results suggest an important role of PI3K/Akt-mediated 





Recent studies have demonstrated that enhanced levels of oxidative stress contribute 
to neuronal death in various pathological conditions including brain ischemia and 
neurodegeneration (for review, Mehta et al., 2007, Bossy-Wetzel et al., 2004). Cerebral 
ischemia / reperfusion causes rapid production of reactive oxygen species (ROS) which 
easily overwhelms the anti-oxidative capacity of the brain. In those conditions, ROS can be 
generated through the activation of NMDA receptors, xanthine oxidation, NADPH oxidation 
and lipid peroxidation. Several stress-associated signaling cascades such as mitogen-activated 
protein kinases (MAP kinases) are activated by ROS, and cause neuronal death directly or 
indirectly via increased production of inflammatory cytokines. In neurodegenerative diseases, 
in contrast, ROS can be generated through the impairment of intracellular organelles such as 
mitochondria and endoplasmic reticulum (ER), or inflammatory response derived from glial 
cells. Accumulation of aggregation-prone proteins such as amyloid  and -synuclein may 
also contribute to ROS generation (Bossy-Wetzel et al., 2004, Smith et al., 2005, Song et al., 
2004).  From the view of therapeutic potential, therefore, it is important to find small 
anti-oxidants which can cross the blood brain barrier (BBB).  
 Alpha-lipoic acid (LA), or 1,2-dithiolane-3-pentanoic acid is a small sterically 
hindered disulfide molecule that can dissolve in both water and lipid, and cross the BBB (for 
review, Shay et al., 2009). Although LA can exist in both R- and S-enantiomeric forms, 
naturally found -lipoic acid is a R-isomer that can bind to the -amino moiety of lysine 
residues by an amide linkage, thus making this isomer essential as a co-factor in the 
mitochondrial energy metabolism. Chemically synthesized LA, in contrast, is a racemate (a 
mixture of equal amount of R- and S-LA), and is believed to exert additional beneficial 
bioactivities when administered exogenously. These include anti-oxidative activities such as 
chelating metals (Muller et al., 1990), scavenging reactive oxygen species (ROS) (Matsugo et 
al, 1995), recycling / inducing endogenous anti-oxidants (Konishi et al., 1996), 
anti-inflammation (Fuchs et al., 1994), activation of cell signaling (Packer et al., 2011), and 
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enhancement of glucose uptake (Konrad et al., 2001). It was also reported that LA had a 
pro-oxidant activity which leads to cellular adaptation against oxidative stress (Cakatay, 
2006). 
 In neurological fields, accumulating evidence suggests that LA (racemate or R-LA) 
has neuroprotective effects in the models of both brain ischemia (Wolz and Krieglstein, 1996, 
Clark et al., 2001) and neurodegeneration such as Alzheimer’s disease (AD) (Siedlak et al., 
2009) and Parkinson’s disease (PD) (Karunakaran et al., 2007). Although the anti-oxidative 
property has been thought to play a pivotal role in the neuroprotective activity of LA, the 
precise reaction mechanism and the effect of LA enantiomers, especially that of S-LA, are 
not fully understood.  
 We report here that every LA enantiomer (racemate, R-LA or S-LA) most effectively 
prevented cell death induced by drugs which deplete intracellular glutathione in SH-SY5Y 
neuroblastoma cells. The underlying mechanism may include Phosphatidylinositol 3-kinases 
(PI3K) /Akt dependent upregulation of anti-oxidant and /or phase II detoxification genes.  
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Materials and Methods 
Cell cultures. Cells of the human neuroblastoma cell line, SH-SY5Y, were maintained in 
DMEM containing 15% FBS and 50g/ml of penicillin and 100g/ml of streptomycin. These 
cells were kept at 37℃ in humidified 5% CO2/95% air. 
 
Stress conditions. SH-SY5Y cells were cultured in 24-well plates up to 60-70% confluence, 
and treated with various stressors for 24-36 h to reduce the viability to 45-60 % of the control 
cells (non-stressed cells). The stressors used in this study were buthionine sulfoximine (BSO) 
(1mM: purchased from Wako chemicals, Osaka, Japan) which is an inhibitor of -glutamyl 
cysteine ligase (-GCL), the rate-limiting enzyme in glutathione synthesis, diethyl maleate 
(DEM) (150 M: Wako chemicals), which is a chelator of glutathione, hydrogen peroxide 
(H2O2) (22 M: Nacalai Tesque, Kyoto, Japan), MG132 (1M: Nacalai Tesque), which is an 
inhibitor of proteasome, thapsigargin (Tg) (0.2M: Sigma), which is an inhibitor of 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), and tunicamycin (Tm) (1g/ml: Sigma), 
which is an inhibitor of N-linked glycosylation in the ER. The latter two drugs were used to 
cause ER stress. -lipoic acid (LA; racemate, R-LA or S-LA) was provided by Dr. Tetsuya 
Konishi (Niigata University of Pharmacy and Applied Life Sciences). LA was added to the 
cells in the presence or absence of stressors, and incubated for the indicated times. In some 
experiments, the cells were treated with LA for 48 h (pre-treatment) prior to the addition of 
stressors. Chemical inhibitors such as SB202190, a p38 Mitogen-activated protein kinase 
(MAPK) inhibitor (Sigma), LY294002, a Phosphatidylinositol 3-kinases (PI3K) inhibitor 
(Sigma), SP600125, a Jun amino-terminal kinase (JNK) inhibitor (Sigma), PD98059, 
Extracellular signal-regulated kinase (ERK) inhibitor (Sigma), Sn-mesoporphyrin IX 
(Sn-MP), a heme oxygenase-1 (HO-1) inhibitor (Frontier Scientific Inc., Logan, UT), and 
dicoumarol, a NAD(P)H:Quinone Oxidoreductase 1 (NQO1) inhibitor (Tokyo Chemical 




Cell viability and cell death assays. Cell viability and cell death were measured using MTT 
assay (Nacalai Tesque) and LIVE/DEAD assay (Invitrogen, Carlsbad, CA), respectively, as 
described previously (Hori et al., 2004). In the latter experiment, the number of dead cells out 
of the total cells is shown in the graph. 
 
Measurement of total glutathione and ROS.  Total glutathione (GSH/GSSG) content was 
measured using a Total Glutathione Quantification Kit (DOJINDO, Kumamoto, Japan). 
Briefly, SH-SY5Y cells were treated with LA in the presence or absence of 1mM BSO for 
the indicated times. Cells were then harvested, and lysed in 0.2ml of PBS using a sonicator 
(Braoson, Danbury, CT). The samples were deproteinized with 20 l of 5% 5-sulfosalicylic 
acid (SSA: Sigma), and total glutathione was measured following the manufacture’s 
instructions. Intracellular ROS levels were measured using a fluorescent probe, 2’, 
7’-dichlorodihydrofluorescin diacetate (DCFH-DA: Invitrogen) as described previously 
(Takano et al., 2007). SH-SY5Y cells were loaded with 5M DCFH-DA for 20 min and the 
fluorescence measured by a microscope (Nikon TS100-F ECLIPSE) equipped with a CCD 
camera (Hamamatsu Photonics, Shizuoka, Japan). Quantification of the fluorescent intensity 
was performed using Image J (version 1.42, Wayne Rasband, National Institutes of health), 
and the results presented as a percentage to the control intensity. 
  
Cell lysis, Western blotting and immunostaining. Cells were lysed in RIPA buffer containing 
10mM Tris, 1mM EDTA, 150mM NaCl, 1% NP-40, 0.1% SDS, 0.2% sodium deoxycholate 
and protease inhibitors. Samples were then subjected to Western blotting with anti-p-ERK 
antibody, anti-ERK antibody, anti-p-JNK antibody, anti-JNK antibody, anti-p-Akt antibody, 
and anti-Akt antibody (Cell Signaling technology, Beverly, MA). Sites of primary antibody 
binding were visualized using alkaline phosphatase-conjugated secondary antibodies. 
Immunostaining was performed with anti- NF-E2-related factor 2 (Nrf2) antibody (Santa 
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Cruz Biotechnology, Inc. Santa Cruz, CA) after fixing the cells. FITC-labled anti-rabbit IgG 
was used as secondary antibody. Nucleus was visualized with DAPI (Sigma).  
 
Quantitative real time RT-PCR (qRT-PCR). Total RNA was extracted from the SH-SY5Y 
cells using TRIzol (Invitrogen). RT reactions containing 1 g of total RNA were performed 
using PrimeScript (Takara, Shiga, Japan). The individual cDNA species were amplified in a 
reaction mixture containing THUNDERBIRDTM SYBR qPCR® Mix (TOYOBO CO, LTD, 
Osaka, Japan) and specific primers for HO-1, NQO1, manganese superoxide dismutase 
(MnSOD), thioredoxin (Trx), and -actin. Comparative Ct method was employed for data 
analysis using MxPro 4.10 (Agilent technologies, Santa Clara, CA). Values for each gene 
were normalized to expression levels of -actin.  
 
Measurement of anti-oxidant capacity. The anti-oxidant capacity was measured using 
Antioxidant Assay Kit (Cayman Chemical Company), which measures the inhibitory effect 
against metmyoglobin-mediated oxidative reaction from 
ABTS(2,2’-azino-di-[3-ethylbenzthiazoline sulphonate] to ABTS.+ 
 
Statistical analysis. Statistical analysis was performed using Bonferroni/Dunn test following 
a one-way ANOVA. Differences were considered statistically significant when p values were 





Protection of SH-SY5Y cells by LA against glutathione depletion. 
 To analyze the neuroprotective effects of LA, human neuroblastoma SH-SY5Y cells 
were treated with different types of stressors such as BSO, H2O2, MG132, tunicamycin (Tm) 
and thapsigargin (Tg). After 24-36 h incubation, cell viability and cell death were measured 
using MTT assay (Fig.1A, C, D, Fig.S1) and LIVE/DEAD assay (Fig.1 B), respectively. 
Each stressor decreased cell viability to 40-60% of control cells (Fig. 1 A, Fig.S1 A). 
Co-treatment of the cells with 100-400 M of LA (racemate) significantly improved cell 
viability against the toxicities induced by BSO (Fig.1 A) and, to a lesser extent, by diethyl 
maleate (DEM) (Fig.S1 B), but not by other stressors (Fig. S1 A), suggesting that LA may 
protect cells most effectively against glutathione depletion. Consistent with these results, 
LIVE/DEAD assay revealed that BSO-induced cell death was attenuated by co-treatment 
with LA (Fig. 1B). Treatment of the cells with LA alone did not affect cell viability (data not 
shown). Next, we compared the neuroprotective properties of each LA-enantiomer (racemate, 
R-LA or S-LA) at lower concentrations (5-50 M) to estimate the dose dependency in 
BSO-treated SH-SY5Y cells. The results revealed that every type of LA significantly 
improved cell viability in a similar manner (Fig. 1 C). As previous reports demonstrated that 
pre-treatment of the cells with LA ameliorated neuronal injury (Zhang et al., 2001, Jia et al., 
2008), we studied the effect of LA pre-treatment in our systems. Cells were incubated under 
three different conditions including treatment with LA in the presence of BSO (co-treatment) 
for 24 h, pre-treatment with LA alone for 48 h followed by BSO treatment for 24 h, and 
pre-treatment with LA alone for 48 h followed by treatment with LA in the presence of BSO 
for 24 h (pre- + co- treatments). In all conditions, LA improved cell viability, but the most 
effective condition was the combination of pre- and co-treatment of LA (Fig. 1D). This 
combined treatment of LA also improved cell viability against the toxicity of H2O2 (Fig. S1 
C), as described previously (Zhang et al., 2001), but not those of other stressors such as 
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MG132, Tm and Tg (data not shown). As IC50 of LA against BSO-induced cell death was 
calculated to be 18.4M in our system, two different concentrations, 20 and 200 M, of LA 
were used for further experiments. 
 
Effects of LA on the amount of intracellular glutathione.  
 As it is known that LA increases intracellular glutathione levels (Shay et al., 2009), 
we hypothesized that LA may protect SH-SY5Y cells against BSO and DEM by modulating 
glutathione content as previously described (Bharath S et al., 2002). The levels of total 
glutathione were measured after LA (racemate) treatment in the presence or absence of BSO. 
Treatment of the cells with LA alone enhanced glutathione levels to 150 % of those in control 
cells both at 16 h and 72 h (48 h+24 h) (Fig. 2 B, C). In contrast, Treatment of the cells with 
BSO alone reduced glutathione levels to 45 %, 20 % and 8 % of those in control cells at 8 h, 
16 h and 24 h, respectively. Treatment of the cells with LA in the presence of BSO for 16 h 
did not restore glutathione levels (Fig. 2 B), and, importantly, pre-treatment of the cells with 
LA for 48 h followed by further treatment with LA in the presence of BSO for 24 h only 
mildly restored the glutathione levels to 15 % of those in control cells (Fig. 2 C), suggesting 
that the protective effect of LA in our system may be different from its 
glutathione-modulating property.  
 
Effects of LA on ROS and oxidative stress response. 
 As LA can reduce oxidative stress directly by attenuating ROS and indirectly by 
enhancing the oxidative stress response, a fluorescent dye DCFH-DA was employed to 
measure the level of ROS. Treatment of SH-SY5Y cells with LA reduced the basal level of 
ROS to 31 % of that in control cells, while treatment of the cells with BSO enhanced it to 
218 % of that in control cells (Fig 3A). Further analysis revealed that treatment of the cells 
with LA in the presence of BSO only mildly reduced ROS levels of the cells treated with 
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BSO alone (189 %) (Fig. 3 A). These results suggested that the direct quenching effect of LA 
toward ROS was not strong enough to scavenge ROS produced in the reaction system. 
 The oxidative stress response was next estimated by analyzing expressions of 
antioxidant genes and phase II detoxification genes at mRNA levels. qRT-PCR analysis 
revealed that downstream genes of Nrf2 such as HO-1 and NQO1 were strikingly upregulated 
by LA in the presence or absence of BSO (Fig. 3 B I, II), as described previously (Jia et al., 
2008, Shay et al., 2009). Similar tendency was obtained when cells were treated with R- or 
S-LA (Fig. S2 A). Immunocytochemical analysis confirmed translocation of Nrf2 from the 
cytosol to the nucleus upon LA treatment (Fig.S2 C). In our system, LA also upregulated 
other anti-oxidant genes such as MnSOD and Trx to lesser degrees (Fig. S2 B I, II). 
Consistent with these results, reduction of anti-oxidant capacity in the cells after BSO 
treatment was restored by co-treatment with LA (Fig. 3 C). 
 To analyze the effect of upregulation of Nrf2-dependent anti-oxidant genes and phase 
II detoxification enzymes (HO-1 and NQO1) on the LA-mediated cell protection, cells were 
treated with Sn-mesoporphyrin IX (Sn-MP), an inhibitor of HO-1, or dicoumarol, an inhibitor 
of NQO1, in the presence or absence of BSO and LA. Dicoumarol (Fig. 3 D), but not Sn-MP 
(data not shown), reduced the protective effect of LA at the doses which did not affect cell 
viability.  
 
Activation of the PI3-kinase/Akt pathway by LA. 
     As it was reported that LA promoted neuronal cell survival through the activation of 
signaling pathways including PI3K / Akt (Zhang et al., 2001, Wang et al., 2009), we 
examined the effect of LA on the phosphorylation of several signaling molecules. Western 
Blot analysis revealed that all LA enantiomers activated Akt (Fig. 4 A I, II), but not ERK 
(Fig. 4 A I), JNK (Fig. 4 A I), or p38 (data not shown), at 1-2h after LA treatment. 
Consistently, the protective effect of LA against BSO was reduced in the cells treated with 
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the PI3K inhibitor (LY294002), but not with the JNK inhibitor (SP600125), the p38 inhibitor 
(SB202190) (Fig. 4 B), or the ERK inhibitor (PD98059) (Fig. S3). 
 To elucidate the effect of Akt activation on the upregulation of antioxidant genes and 
phase II detoxification genes, qRT-PCR was performed using samples derived from cells 
treated with LY294002 in the presence of LA. LY294002 significantly reduced the levels of 




Glutathione is the most abundant antioxidant in the brain which serves to detoxify 
H2O2 by decomposing it into water and oxygen, and keeps the thiol groups of proteins in the 
reduced state (Mytilineou et al., 2002). Numerous studies have demonstrated decreased levels 
of glutathione in pathological conditions including brain ischemia and neurodegenerations. 
Postmortem studies have revealed that glutathione levels in the substantia nigra (SN) are 
decreased with age, and dramatically reduced in the brain of PD patients in concert with the 
death of dopaminergic neurons in the SN (Perry et al., 1982, Perry and Yong, 1986, Riederer 
et al., 1989). In experimental animal studies, acute depletion of glutathione caused extensive 
carbonylation of brain proteins (Bizzozero et al., 2006) and morphological changes of 
dopaminergic neurons in the nigrostriatal pathway that mimic alterations observed in the 
brains of aged animals (Andersen et al., 1996). It is, therefore, critical to find pathways which 
can improve neuronal survival / activity in the glutathione-depleted condition.   
 In this paper, we demonstrated that treatment of the cells with LA most effectively 
prevented cell death induced by drugs which deplete intracellular glutathione in SH-SY5Y 
cells (Fig. 1, Fig. S1). Accumulating evidence has revealed that LA-mediated neuroprotection 
requires relatively long periods of pre-treatment (hours to days) (Zhang et al., 2001, Blarath 
et al., 2002, Wang et al., 2010 ), raising a hypothesis that it may play more critical roles in 
enhancing the defense system against oxidative stress which includes upregulation of 
anti-oxidants such as glutathione and HO-1, and phase II enzymes such as NQO1, than 
directly chelating metals or scavenging reactive oxygen species (ROS) (Shay et al., 2009). 
Consistent with this hypothesis, LA-mediated cell protection against BSO was enhanced in 
the combination of pre-treatment for 48h and co-treatment for 24h in our system (Fig. 1 D). 
H2O2-induced toxicity was also attenuated in the combination of pre- and co-treatment of LA 
(Fig. S1 A II). Furthermore, expressions of endogenous anti-oxidants such as HO-1 and 
phase II enzymes such as NQO1 were strikingly upregulated by LA treatment in the presence 
of BSO (approximately 20-25 fold increase, Fig. 3 B I, II). The reduction of anti-oxidant 
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capacity upon BSO treatment was also restored by treatment with LA (Fig. 3 C). Furthermore, 
an inhibitor of NQO1, but not HO-1, significantly reduced the protective effect of LA against 
BSO (Fig. 3 D). In contrast, LA had only mild effects on BSO-mediated glutathione 
depletion (Fig. 2) or ROS generation (Fig. 3 A).  
 How does LA enhance the defense system against oxidative stress? One possibility is 
activation of signaling pathways such as PI3K/Akt, p38 MAPK, ERK1/2 and JNK (Shay et 
al., 2009). Consistent with previous reports (Zhang et al., 2001, Abdul et al., 2007), LA 
activated Akt (Fig. 4 A), and an inhibitor of PI3K, LY294002, suppressed the effect of LA on 
NQO1 expression (Fig. 4 C) and cell viability upon BSO treatment (Fig. 4 B). Another 
possibility is that LA, as a pro-oxidant, increases both Nrf2-dependent and independent 
transcriptional activity (Shay et al., 2009). Mild upregulation of MnSOD and Trx expressions 
(approximately 3-3.5 fold increase, Fig. S2 B, I, II) upon LA treatment in the presence of 
BSO may support this, but this is not so likely because the level of ROS was not enhanced 
either in the cells (Fig. 3 A) or in the media (unpublished observation) after LA treatment.  
 Regarding LA enantiomers, every LA (racemate, R-LA or S-LA) protected cells 
against BSO toxicity (Fig. 1 C) and upregulated endogenous anti-oxidants (Fig. 3 B, Fig. S 2 
A) in a similar manner. Previous reports demonstrated that R- and S-LA are differentially 
metabolized, and R-LA may exert more rapid and clearer bioactivities (e.g. glucose uptake 
and glycogen synthesis) than S-LA (Shay et al., 2009). Further studies are required, 
especially in vivo, to determine the differences between LA enantiomers for their 
neuroprotective properties.   
 In conclusion, we demonstrated that all LA enantiomers most effectively prevented 
cell death induced by drugs which deplete glutathione through several mechanisms including 
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Figure 1. Effects of LA on BSO toxicity.  (A), (B) Improved viability and reduced cell death 
in LA-treated cells. SH-SY5Y cells were treated with BSO at the indicated concentrations for 
36h in the presence or absence of LA (racemate). Cell viability and death were measured 
using MTT assay (A) and LIVE/DEAD assay (B), respectively. (C) Effects of 
LA-enantiomers on BSO toxicity. Cells were treated with 1mM of BSO in the presence or 
absence of LA enantiomers (racemate, R-LA or S-LA) at indicated concentrations. Cell 
viability was measured using MTT assay. (D) The effect of LA pretreatment on the BSO 
toxicity. Cells were treated with LA in the presence of BSO for 24 h, pre-treated with LA 
alone for 48 h followed by BSO treatment for 24 h, or pre-treated with LA alone for 48 h 
followed by treatment with LA in the presence of BSO for 24 h. Cell viability was measured 
using MTT assay. Values shown are the mean  S.D. in three separate experiments. *P<0.05, 
**P<0.01, significantly different from values obtained under treatment with BSO alone. 
#P<0.05, significantly different between the two conditions. 
 
Figure 2. Effects of LA on the amount of glutathione.  Cells were treated with LA 
(racemate) for 8h (A) or 16h (B) in the presence or absence of BSO. Cells were also treated 
with LA (racemate) for 48h, followed by treatment with LA in the presence or absence of 
BSO for further 24h (C). The amount of intracellular glutathione was measured as described 
in the text. The values in the cells cultured in the medium alone were designated as 100. 
Values shown are the mean  S.D. in three separate experiments. *P<0.05, **P<0.01, 
significantly different between the two conditions. 
 
Figure 3. Effects of LA on ROS generation and oxidative stress response.  (A) Measurement 
of ROS using a fluorescent dye DCFH-DA. Cells were treated with LA in the presence or 
absence of 1mM BSO for 16h, and then loaded with 5M DCFH-DA for 20min. Typical 
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results were demonstrated (I). Quantification was performed using Image J as described in 
the text (II). (B) Upregulation of anti-oxidant genes. Cells were treated with LA in the 
presence or absence of 1mM BSO for 16h, and total RNA was extracted. qRT-PCR was 
performed with specific primers for HO-1 (I) and NQO1 (II). Values shown are the mean  
S.D. in four separate experiments. (C) Anti-oxidant capacity upon BSO treatment. Cells were 
treated with LA in the presence of BSO for 28h, and anti-oxidant assay was performed as 
described in the text. (D) Effect of dicoumarol on LA-mediated protection against BSO. Cells 
were treated with the indicated dose of dicoumarol in the presence and absence of BSO and 
LA for 36h. Cell viability was analyzed using MTT assay. Values shown are the mean  S.D. 
in three separate experiments. *P<0.05, **P<0.01, significantly different from values 
obtained under incubation in the medium alone. #P<0.05 , significantly different between the 
two conditions. 
 
Figure 4. Activation of PI3K / Akt pathway by LA. (A) Phosphorylation of stress-associated 
kinases after LA treatment. Cells were treated with 200M LA (racemate, R-LA or S-LA) for 
the indicated times, and protein extracts were subjected to Western blotting using the 
indicated antibodies (I). Relative intensity was measured using Image J as described in the 
text (II). (B) Effects of kinase inhibitors on LA-mediated cell protection. Cells were treated 
with the indicated kinase inhibitors in the presence or absence of BSO and LA for 36h, and 
MTT assay was performed. Values shown are the mean  S.D. in three separate experiments. 
(C) Suppression of LA-mediated NQO1 upregulation by PI3K inhibitor. Cells were treated 
with LY294002 in the presence of LA for 24h, and total RNA was extracted. qRT-PCR was 
performed with specific primers for NQO1. Values shown are the mean  S.D. in four 
separate experiments. *P<0.05, **P<0.01, significantly different from values in the 
conditions incubated in the medium alone. #P<0.05 , significantly different between the two 
conditions. 
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-lipoic acid (LA) enantiomers protect SH-SY5Y cells 
against glutathione depletion 
 
Supplemental Figure Legends 
 
Figure S1. (A) (B) Effects of LA on cell viability during different stresses. SH-SY5Y cells 
were treated with LA in the presence of various stressors such as H2O2 (24h), MG132 (24h), 
tunicamycin (Tm) (24h), thapsigargin (Tg) (24h) (A) or DEM (36h) (B), and MTT assay was 
performed. Values shown are the mean  S.D. in three separate experiments. *P<0.05, 
significantly different from values obtained under treatment with BSO alone. (C) The effect 
of LA pretreatment on the H2O2 toxicity. Cells were pre-treated with LA alone for 48 h 
followed by treatment with LA in the presence of H2O2 for 24 h. Cell viability was measured 
using MTT assay. Values shown are the mean  S.D. in three separate experiments. *P<0.05, 
**P<0.01, significantly different from values obtained under treatment with BSO or 
H2O2alone. 
 
Figure S2.  Upregulation of anti-oxidant genes and Nrf2 activation by LA. Cells were 
treated with LA (racemate, R-LA or S-LA) in the presence or absence of 1mM BSO for 16h. 
(A)(B) Expressions of anti-oxidant genes. Total RNA was subjected to qRT-PCR with 
specific primers for NQO1 (A), MnSOD (B I), or Trx (B II). Values shown are the mean  
S.D. in four separate experiments. *P<0.05, **P<0.01, significantly different from values 
obtained under incubation in the medium alone. (C) Cells were fixed and subjected to 
immunostaining with anti-Nrf2 antibody. Nucleus was visualized with DAPI.  
 
Figure S3.  Effect of an ERK inhibitor on LA-mediated cell protection. Cells were treated 
with PD98059 in the presence of BSO and LA for 36h, and MTT assay was performed. 
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Values shown are the mean  S.D. in three separate experiments. **P<0.01, significantly 
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Fig.S2 Yamada et al.
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Fig.S3 Yamada et al.
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